Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
236
NCT00725881
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2008
Completion: Mar 31, 2010
NCT00826930
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
Phase: Phase 1
Start: Mar 31, 2009
Completion: May 31, 2009
NCT01465347
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Start: Feb 29, 2012
Completion: Feb 29, 2016
NCT03393000
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Phase: Phase 3
Start: Jan 16, 2018
Completion: Nov 6, 2020
NCT03763929
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
Phase: Phase 2
Start: Aug 22, 2019
Completion: Oct 19, 2020
NCT04573322
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
Start: Sep 10, 2020
Completion: Apr 29, 2021
NCT04808622
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers
Start: Mar 17, 2021
Completion: Mar 25, 2021
NCT05036980
Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude
Start: Nov 9, 2021
Completion: Apr 10, 2022
NCT05079126
Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Start: Dec 2, 2021
Completion: May 27, 2022